No Intervention: Observational Cohort: Observation study
An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients with Type 2 Diabetes Primary Research Objective
• To evaluate the safety of Henagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM) in real world.
Exploratory Research Objectives
* 1\. Improvement in metabolic parameters: To assess changes in metabolic indicators, including glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG), blood pressure, and body weight, in T2DM patients treated with Henagliflozin.
* 2\. Incidence of specific adverse events: To investigate the occurrence of key adverse events, with a focus on hypovolemia, amputation or amputation risk, fractures, urinary tract infections, genital infections, renal impairment, diabetic ketoacidosis, hepatic dysfunction, and severe hypoglycemia.
* 3\. Impact on muscle health: To evaluate changes in muscle health indicators, such as skeletal muscle mass index, lean body mass, and grip strength, in T2DM patients receiving Henagliflozin therapy.
| Facility | City | Region | Status |
|---|---|---|---|
| The People's Hospital of Beihai | Beihai | Guangxi | Not Yet Recruiting |
| Guilin Municipal Hospital of Traditional Chinese Medicine | Guilin | Guangxi | Not Yet Recruiting |
| Nanxishan Hospital of Guangxi Zhuang Autonomous Region | Nanning | Guangxi | Not Yet Recruiting |
| The People's Hospital of Guangxi Zhuang Autonomous Region | Nanning | Guangxi | Not Yet Recruiting |
| The People's Hospital of Guangxi Zhuang Autonomous Region | Nanning | Guangxi | Not Yet Recruiting |
| the Second Affiliated Hospital of Guangxi Medical University | Nanning | Guangxi | Recruiting |
| Qingdao Aikangyi Internet Hospital | Qingdao | Shandong | Not Yet Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06959030 on ClinicalTrials.gov ↗ ← All trials in China